The report covers forecast and analysis for the Lymphoedema Diagnostics market on a global and regional level. The study provides historic data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints for the Lymphoedema Diagnostics market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Lymphoedema Diagnostics market on a global level. In order to give the users of this report a comprehensive view on the Lymphoedema Diagnostics market we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein technology, disease type, end user and regional segments are benchmarked based on their market size, growth rate and general attractiveness.
Lymphedema is an incurable but treatable medical condition that is caused by lymphatic system damage, trauma or congenital defects. When the damage develops greatly that the lymphatic fluid goes beyond the lymphatic transportation capacity, swelling results in the tissues of the affected area as an unusual amount of protein-rich fluid. There are two lymphedema types, primary and secondary. At birth (congenital) or at the beginning of puberty (praecox) or in adulthood (tarda), primary lymphedema may occur. Secondary lymphedema may be caused by surgery or radiation therapy and is a common result of cancer treatments that eliminate or harm lymph nodes or vessels.
The study provides a decisive view on the Lymphoedema Diagnostics market by segmenting the market based on technology, disease type, end user and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2025. Based on technology, the market is segmented into X-ray Lymphography, Lymphoscintigraphy, Computed Tomography, Ultrasound Imaging, Magnetic Resonance Imaging, Bioimpedance Analysis, Near-infrared Fluorescence Imaging, ICG Lymphography and Fluorescein Sodium Microlymphangiography. The field of lymphoscintigraphy represented the largest market share in 2018. The non-invasive design and simple reproducibility of this technique, as well as the point that lymphatic vascular endothelium is not badly affected by lymphoscintigraphy, are some of the significant advantages that endorse this technology's adoption.
Based on disease type, the market is segmented into Cancer, Cardiovascular Disease, Inflammatory Diseases and Other Diseases. In 2018, the cancer group represented the largest market share. The large proportion of this section can be due to the increased prevalence of lymphedema associated with cancer and increased awareness of early diagnosis of disease. Based on end user, the market is segmented into hospitals, diagnostic centers, research & academic institutes and other end users. The segment of hospitals was the largest market share in 2018. The large proportion of this section can be due to the large number of hospital-based lymphedema diagnostic procedures, the growing acceptance of minimally invasive procedures, and the increasing adoption of advanced imaging modalities to increase hospital-based workflow performance. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific region is one of the chief revenue-generating regions in the market. This market is also expected to show high growth in the coming years, mainly due to the increasing incidence of chronic diseases, growing awareness about the benefits of early lymphedema diagnosis, improvements in healthcare systems, and growing research activities related to the development of advanced lymphedema diagnostic modalities.
Increasing prevalence of lymphedema and cancer; technological advances in modalities of diagnostic imaging; and increasing public-private organizations ' investments, funds, and grants are the major drivers of this market's growth.
Key players within global Lymphoedema Diagnostics market include Bausch Health Companies, Galderma S.A., Celtic Pharma, Anacor pharmaceuticals, Inc., Johnson & Johnson, Novartis AG, Pfizer Inc., GlaxoSmithKline, Topica Pharmaceuticals, Inc., Moberg Pharma AB, Bayer AG, Dr. Reddy’s Laboratories Ltd, Allergen, Inc., Cipla Ltd, Medimetriks Pharmaceuticals Inc., Sanofi S.A., NovaBiotics Inc., and Merz Pharma. amongst others.
The report segments global Lymphoedema Diagnostics market as follows:
Global Lymphoedema Diagnostics Market: Technology Segment Analysis
Global Lymphoedema Diagnostics Market: Disease type Segment Analysis
Global Lymphoedema Diagnostics Market: Distribution Channel Segment Analysis
Global Lymphoedema Diagnostics Market: Regional Segment Analysis
Lymphedema is an incurable but treatable medical condition that is caused by lymphatic system damage, trauma or congenital defects. When the damage develops greatly that the lymphatic fluid goes beyond the lymphatic transportation capacity, swelling results in the tissues of the affected area as an unusual amount of protein-rich fluid. There are two lymphedema types, primary and secondary. At birth (congenital) or at the beginning of puberty (praecox) or in adulthood (tarda), primary lymphedema may occur. Secondary lymphedema may be caused by surgery or radiation therapy and is a common result of cancer treatments that eliminate or harm lymph nodes or vessels.
The study provides a decisive view on the Lymphoedema Diagnostics market by segmenting the market based on technology, disease type, end user and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2025. Based on technology, the market is segmented into X-ray Lymphography, Lymphoscintigraphy, Computed Tomography, Ultrasound Imaging, Magnetic Resonance Imaging, Bioimpedance Analysis, Near-infrared Fluorescence Imaging, ICG Lymphography and Fluorescein Sodium Microlymphangiography. The field of lymphoscintigraphy represented the largest market share in 2018. The non-invasive design and simple reproducibility of this technique, as well as the point that lymphatic vascular endothelium is not badly affected by lymphoscintigraphy, are some of the significant advantages that endorse this technology's adoption.
Based on disease type, the market is segmented into Cancer, Cardiovascular Disease, Inflammatory Diseases and Other Diseases. In 2018, the cancer group represented the largest market share. The large proportion of this section can be due to the increased prevalence of lymphedema associated with cancer and increased awareness of early diagnosis of disease. Based on end user, the market is segmented into hospitals, diagnostic centers, research & academic institutes and other end users. The segment of hospitals was the largest market share in 2018. The large proportion of this section can be due to the large number of hospital-based lymphedema diagnostic procedures, the growing acceptance of minimally invasive procedures, and the increasing adoption of advanced imaging modalities to increase hospital-based workflow performance. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific region is one of the chief revenue-generating regions in the market. This market is also expected to show high growth in the coming years, mainly due to the increasing incidence of chronic diseases, growing awareness about the benefits of early lymphedema diagnosis, improvements in healthcare systems, and growing research activities related to the development of advanced lymphedema diagnostic modalities.
Increasing prevalence of lymphedema and cancer; technological advances in modalities of diagnostic imaging; and increasing public-private organizations ' investments, funds, and grants are the major drivers of this market's growth.
Key players within global Lymphoedema Diagnostics market include Bausch Health Companies, Galderma S.A., Celtic Pharma, Anacor pharmaceuticals, Inc., Johnson & Johnson, Novartis AG, Pfizer Inc., GlaxoSmithKline, Topica Pharmaceuticals, Inc., Moberg Pharma AB, Bayer AG, Dr. Reddy’s Laboratories Ltd, Allergen, Inc., Cipla Ltd, Medimetriks Pharmaceuticals Inc., Sanofi S.A., NovaBiotics Inc., and Merz Pharma. amongst others.
The report segments global Lymphoedema Diagnostics market as follows:
Global Lymphoedema Diagnostics Market: Technology Segment Analysis
- X-ray Lymphography
- Lymphoscintigraphy
- Computed Tomography
- Ultrasound Imaging
- Magnetic Resonance Imaging
- Bioimpedance Analysis
- Near-infrared Fluorescence Imaging
- ICG Lymphography
- Fluorescein Sodium Microlymphangiography
Global Lymphoedema Diagnostics Market: Disease type Segment Analysis
- Cancer
- Cardiovascular Disease
- Inflammatory Diseases
- Other Diseases
Global Lymphoedema Diagnostics Market: Distribution Channel Segment Analysis
- Hospital Pharmacies
- Retail Pharmacies
- Others
Global Lymphoedema Diagnostics Market: Regional Segment Analysis
- North America
- U.S.
- Europe
- UK
- France
- Germany
- Asia Pacific
- China
- Japan
- India
- Latin America
- Brazil
- Middle East and Africa
Table of Contents
- Chapter 1. Preface
- 1.1. Report Description and Scope
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology
- Chapter 2. Executive Summary
- 2.1. Lymphoedema Diagnostics Market, 2016-2025 (USD Million)
- 2.2. Lymphoedema Diagnostics Market: Snapshot
- Chapter 3. Lymphoedema Diagnostics Market - Industry Analysis
- 3.1. Lymphoedema Diagnostics Market: Market Dynamics
- 3.2. Market Drivers
- 3.2.1. Driver 1
- 3.2.2. Driver 2
- 3.3. Restraints
- 3.3.1. Restraint 1
- 3.3.2. Restraint 2
- 3.4. Opportunity
- 3.4.1. Government funding and support
- 3.5. Porter's Five Forces Analysis
- 3.6. Market Attractiveness Analysis
- 3.6.1. Market attractiveness analysis By Product
- 3.6.2. Market attractiveness analysis By Disease type
- 3.6.3. Market attractiveness analysis By Distribution Channel
- 3.6.4. Market attractiveness analysis By Region
- Chapter 4. Lymphoedema Diagnostics Market- Competitive Landscape
- 4.1. Company market share analysis
- 4.1.1. Global Lymphoedema Diagnostics Market: company market share, 2018
- 4.2. Strategic development
- 4.2.1. Acquisitions & mergers
- 4.2.2. New Product launches
- 4.2.3. Agreements, partnerships, collaborations and joint ventures
- 4.2.4. Research and development and Regional expansion
- 4.3. Price trend analysis
- 4.1. Company market share analysis
- Chapter 5. Global Lymphoedema Diagnostics Market - Technology Analysis
- 5.1. Global Lymphoedema Diagnostics Market overview: By Technology
- 5.1.1. Global Lymphoedema Diagnostics Market share, By Product,2018 and 2025
- 5.2. X-ray Lymphography
- 5.2.1. Global Lymphoedema Diagnostics Market By Product1, 2016-2025 (USD Million)
- 5.3. Lymphoscintigraphy
- 5.3.1. Global Lymphoedema Diagnostics Market By Product2, 2016-2025 (USD Million)
- 5.4. Computed Tomography
- 5.4.1. Global Lymphoedema Diagnostics Market By Product3, 2016-2025 (USD Million)
- 5.5. Ultrasound Imaging
- 5.5.1. Global Lymphoedema Diagnostics Market By Product4, 2016-2025 (USD Million)
- 5.6. Bioimpedance Analysis
- 5.6.1. Global Lymphoedema Diagnostics Market By Bioimpedance Analysis, 2016-2025 (USD Million)
- 5.7. Near-infrared Fluorescence Imaging
- 5.7.1. Global Lymphoedema Diagnostics Market By Near-infrared Fluorescence Imaging, 2016-2025 (USD Million)
- 5.8. ICG Lymphography
- 5.8.1. Global Lymphoedema Diagnostics Market By ICG Lymphography, 2016-2025 (USD Million)
- 5.9. Fluorescein Sodium Microlymphangiography
- 5.9.1. Global Lymphoedema Diagnostics Market By Fluorescein Sodium Microlymphangiography, 2016-2025 (USD Million)
- 5.1. Global Lymphoedema Diagnostics Market overview: By Technology
- Chapter 6. Global Lymphoedema Diagnostics Market -Disease type Analysis
- 6.1. Global Lymphoedema Diagnostics Market overview: By Disease type
- 6.1.1. Global Lymphoedema Diagnostics Market share, By Disease type, 2018 and 2025
- 6.2. Cancer
- 6.2.1. Global Lymphoedema Diagnostics Market By Cancer, 2016-2025 (USD Million)
- 6.3. Cardiovascular Disease
- 6.3.1. Global Lymphoedema Diagnostics Market By Cardiovascular Disease, 2016-2025 (USD Million)
- 6.4. Inflammatory Diseases
- 6.4.1. Global Lymphoedema Diagnostics Market By Inflammatory Diseases, 2016-2025 (USD Million)
- 6.5. Others
- 6.5.1. Global Lymphoedema Diagnostics Market By Other Disease types, 2016-2025 (USD Million)
- 6.1. Global Lymphoedema Diagnostics Market overview: By Disease type
- Chapter 7. Global Lymphoedema Diagnostics Market -Distribution Channel Analysis
- 7.1. Global Lymphoedema Diagnostics Market overview: By Distribution Channel
- 7.1.1. Global Lymphoedema Diagnostics Market share, By Distribution Channel, 2018 and 2025
- 7.2. Hospital Pharmacies
- 7.2.1. Global Lymphoedema Diagnostics Market By Hospital Pharmacies, 2016-2025 (USD Million)
- 7.3. Retail Pharmacies
- 7.3.1. Global Lymphoedema Diagnostics Market By Retail Pharmacies, 2016-2025 (USD Million)
- 7.4. Others
- 7.4.1. Global Lymphoedema Diagnostics Market By others, 2016-2025 (USD Million)
- 7.1. Global Lymphoedema Diagnostics Market overview: By Distribution Channel
- Chapter 8. Global Lymphoedema Diagnostics Market - Regional Analysis
- 8.1. Global Lymphoedema Diagnostics Market overview: By Region
- 8.1.1. Global Lymphoedema Diagnostics Market share, By Region, 2018 and 2025
- 8.2. North America
- 8.2.1. North America Lymphoedema Diagnostics Market, 2016-2025 (USD Million)
- 8.2.2. North America Lymphoedema Diagnostics Market revenue, By Product,2016-2025 (USD Million)
- 8.2.3. North America Lymphoedema Diagnostics Market revenue, By Disease type, 2016-2025 (USD Million)
- 8.2.4. North America Lymphoedema Diagnostics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
- 8.2.5. The U.S.
- 8.2.5.1. The U.S.Lymphoedema Diagnostics Market revenue, By Product,2016-2025 (USD Million)
- 8.2.5.2. The U.S.Lymphoedema Diagnostics Market revenue, By Disease type, 2016-2025 (USD Million)
- 8.2.5.3. The U.S.Lymphoedema Diagnostics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
- 8.2.6. Rest of North America
- 8.2.6.1. Rest of North America Lymphoedema Diagnostics Market revenue, By Product,2016-2025 (USD Million)
- 8.2.6.2. Rest of North America Lymphoedema Diagnostics Market revenue, By Disease type, 2016-2025 (USD Million)
- 8.2.6.3. Rest of North America Lymphoedema Diagnostics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
- 8.3. Europe
- 8.3.1. EuropeLymphoedema Diagnostics Market 2016-2025 (USD Million)
- 8.3.2. Europe Lymphoedema Diagnostics Market revenue, By Product,2016-2025 (USD Million)
- 8.3.3. Europe Lymphoedema Diagnostics Market revenue, By Disease type, 2016-2025 (USD Million)
- 8.3.4. Europe Lymphoedema Diagnostics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
- 8.3.5. UK
- 8.3.5.1. U.K.Lymphoedema Diagnostics Market revenue, By Product,2016-2025 (USD Million)
- 8.3.5.2. U.K.Lymphoedema Diagnostics Market revenue, By Disease type, 2016-2025 (USD Million)
- 8.3.5.3. U.K. Lymphoedema Diagnostics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
- 8.3.6. France
- 8.3.6.1. France Lymphoedema Diagnostics Market revenue, By Product,2016-2025 (USD Million)
- 8.3.6.2. France Lymphoedema Diagnostics Market revenue, By Disease type, 2016-2025 (USD Million)
- 8.3.6.3. France Lymphoedema Diagnostics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
- 8.3.7. Germany
- 8.3.7.1. Germany Lymphoedema Diagnostics Market revenue, By Product,2016-2025 (USD Million)
- 8.3.7.2. Germany Lymphoedema Diagnostics Market revenue, By Disease type, 2016-2025 (USD Million)
- 8.3.7.3. Germany Lymphoedema Diagnostics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
- 8.3.8. Rest of Europe
- 8.3.8.1. Rest of EuropeLymphoedema Diagnostics Market revenue, By Product,2016-2025 (USD Million)
- 8.3.8.2. Rest of EuropeLymphoedema Diagnostics Market revenue, By Disease type, 2016-2025 (USD Million)
- 8.3.8.3. Rest of Europe Lymphoedema Diagnostics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
- 8.4. Asia Pacific
- 8.4.1. Asia Pacific Lymphoedema Diagnostics Market, 2016-2025 (USD Million)
- 8.4.2. Asia Pacific Lymphoedema Diagnostics Market revenue, By Product,2016-2025 (USD Million)
- 8.4.3. Asia Pacific Lymphoedema Diagnostics Market revenue, By Disease type, 2016-2025 (USD Million)
- 8.4.4. Asia Pacific Lymphoedema Diagnostics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
- 8.4.5. China
- 8.4.5.1. China Lymphoedema Diagnostics Market revenue, By Product,2016-2025 (USD Million)
- 8.4.5.2. China Lymphoedema Diagnostics Market revenue, By Disease type, 2016-2025 (USD Million)
- 8.4.5.3. China Lymphoedema Diagnostics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
- 8.4.6. Japan
- 8.4.6.1. Japan Lymphoedema Diagnostics Market revenue, By Product,2016-2025 (USD Million)
- 8.4.6.2. Japan Lymphoedema Diagnostics Market revenue, By Disease type, 2016-2025 (USD Million)
- 8.4.6.3. Japan Lymphoedema Diagnostics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
- 8.4.7. India
- 8.4.7.1. India Lymphoedema Diagnostics Market revenue, By Product,2016-2025 (USD Million)
- 8.4.7.2. India Lymphoedema Diagnostics Market revenue, By Disease type, 2016-2025 (USD Million)
- 8.4.7.3. India Lymphoedema Diagnostics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
- 8.4.8. Rest of Asia Pacific
- 8.4.8.1. Rest of Asia Pacific Lymphoedema Diagnostics Market revenue, By Product,2016-2025 (USD Million)
- 8.4.8.2. Rest of Asia Pacific Lymphoedema Diagnostics Market revenue, By Disease type, 2016-2025 (USD Million)
- 8.4.8.3. Rest of Asia Pacific Lymphoedema Diagnostics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
- 8.5. Latin America
- 8.5.1. Latin America Lymphoedema Diagnostics Market, 2016-2025 (USD Million)
- 8.5.2. Latin America Lymphoedema Diagnostics Market revenue, By Product,2016-2025 (USD Million)
- 8.5.3. Latin America Lymphoedema Diagnostics Market revenue, By Disease type, 2016-2025 (USD Million)
- 8.5.4. Latin America Lymphoedema Diagnostics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
- 8.5.5. Brazil
- 8.5.5.1. Brazil Lymphoedema Diagnostics Market revenue, By Product,2016-2025 (USD Million)
- 8.5.5.2. Brazil Lymphoedema Diagnostics Market revenue, By Disease type, 2016-2025 (USD Million)
- 8.5.5.3. Brazil Lymphoedema Diagnostics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
- 8.5.6. Rest of Latin America
- 8.5.6.1. Rest of Latin America Lymphoedema Diagnostics Market revenue, By Product,2016-2025 (USD Million)
- 8.5.6.2. Rest of Latin America Lymphoedema Diagnostics Market revenue, By Disease type, 2016-2025 (USD Million)
- 8.5.6.3. Rest of Latin America Lymphoedema Diagnostics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
- 8.6. The Middle East and Africa
- 8.6.1. The Middle East and Africa Lymphoedema Diagnostics Market, 2016-2025 (USD Million)
- 8.6.2. The Middle East and Africa Lymphoedema Diagnostics Market revenue, By Product,2016-2025 (USD Million)
- 8.6.3. The Middle East and Africa Lymphoedema Diagnostics Market revenue, By Disease type, 2016-2025 (USD Million)
- 8.6.4. The Middle East and Africa Lymphoedema Diagnostics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
- 8.1. Global Lymphoedema Diagnostics Market overview: By Region
- Chapter 9. Company Profiles
- 9.1. Bausch Health Companies
- 9.1.1. Overview
- 9.1.2. Financials
- 9.1.3. Product Portfolio
- 9.1.4. Business Strategy
- 9.1.5. Recent Developments
- 9.2. Galderma S.A
- 9.2.1. Overview
- 9.2.2. Financials
- 9.2.3. Product Portfolio
- 9.2.4. Business Strategy
- 9.2.5. Recent Developments
- 9.3. Celtic Pharma
- 9.3.1. Overview
- 9.3.2. Financials
- 9.3.3. Product Portfolio
- 9.3.4. Business Strategy
- 9.3.5. Recent Developments
- 9.4. Anacor pharmaceuticals, Inc.
- 9.4.1. Overview
- 9.4.2. Financials
- 9.4.3. Product Portfolio
- 9.4.4. Business Strategy
- 9.4.5. Recent Developments
- 9.5. Johnson & Johnson
- 9.5.1. Overview
- 9.5.2. Financials
- 9.5.3. Product Portfolio
- 9.5.4. Business Strategy
- 9.5.5. Recent Development
- 9.6. Novartis AG, Pfizer Inc.
- 9.6.1. Overview
- 9.6.2. Financials
- 9.6.3. Product Portfolio
- 9.6.4. Business Strategy
- 9.6.5. Recent Development
- 9.7. GlaxoSmithKline
- 9.7.1. Overview
- 9.7.2. Financials
- 9.7.3. Product Portfolio
- 9.7.4. Business Strategy
- 9.7.5. Recent Development
- 9.8. Topica Pharmaceuticals, Inc.
- 9.8.1. Overview
- 9.8.2. Financials
- 9.8.3. Product Portfolio
- 9.8.4. Business Strategy
- 9.8.5. Recent Development
- 9.9. Moberg Pharma AB
- 9.9.1. Overview
- 9.9.2. Financials
- 9.9.3. Product Portfolio
- 9.9.4. Business Strategy
- 9.9.5. Recent Development
- 9.10. Bayer AG
- 9.10.1. Overview
- 9.10.2. Financials
- 9.10.3. Product Portfolio
- 9.10.4. Business Strategy
- 9.10.5. Recent Development
- 9.1. Bausch Health Companies
